ReviewFrontiers in neurology2025
Psoriasis: an emerging risk factor for ischemic stroke?
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Autoimmune diseases are associated with increased neurodegenerative and cerebrovascular risk, while systemic corticosteroid exposure shows limited neurodegenerative and modest vascular associations.IBRO neuroscience reports · 2026Article
- Methotrexate Exposure and Inflammatory-Metabolic Biomarker Networks in Hospitalized Patients with Psoriasis: A Network Analysis Approach.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2020 nearly 12 million people worldwide suffered a stroke, and acute ischemic stroke (AIS) is the most frequent stroke subtype, accounting for approximately 65% of total stroke incidence. Therefore, primary prevention, including non-traditional risk factors, should be recognized as a major public health priority. Research has shown that autoimmune diseases associated with chronic systemic inflammation, such as psoriasis, are commonly linked to AIS incidence. Psoriasis is a chronic autoimmune erythematous-squamous disease that primarily affects the skin, nails, and joints. Psoriasis is known to be a systemic inflammatory condition affecting multiple organs. Patients with psoriasis are at a higher risk of stroke than the general population, and a more severe disease course can increase this risk by up to 44%. One possible explanation for this phenomenon is that chronic systemic inflammation is associated with endothelial dysfunction and atherosclerotic plaque development. On the other hand, patients with psoriasis have an increased prevalence of traditional cardiovascular risk factors, including metabolic syndrome. This narrative review synthesizes the scientific literature to provide a comprehensive overview of the current understanding of the association between psoriasis and AIS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.